RU2015128496A3 - - Google Patents

Download PDF

Info

Publication number
RU2015128496A3
RU2015128496A3 RU2015128496A RU2015128496A RU2015128496A3 RU 2015128496 A3 RU2015128496 A3 RU 2015128496A3 RU 2015128496 A RU2015128496 A RU 2015128496A RU 2015128496 A RU2015128496 A RU 2015128496A RU 2015128496 A3 RU2015128496 A3 RU 2015128496A3
Authority
RU
Russia
Application number
RU2015128496A
Other languages
Russian (ru)
Other versions
RU2686670C2 (ru
RU2015128496A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2015128496A publication Critical patent/RU2015128496A/ru
Publication of RU2015128496A3 publication Critical patent/RU2015128496A3/ru
Application granted granted Critical
Publication of RU2686670C2 publication Critical patent/RU2686670C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2015128496A 2013-10-04 2014-10-03 Лечение аллергического ринита с использованием комбинации мометазона и олопатадина RU2686670C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3174MU2013 2013-10-04
IN3174MUM2013 2013-10-04
PCT/IB2014/065035 WO2015049665A1 (en) 2013-10-04 2014-10-03 Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2019104453A Division RU2799761C2 (ru) 2013-10-04 2014-10-03 Лечение аллергического ринита с использованием комбинации мометазона и олопатадина

Publications (3)

Publication Number Publication Date
RU2015128496A RU2015128496A (ru) 2017-11-13
RU2015128496A3 true RU2015128496A3 (enExample) 2018-06-19
RU2686670C2 RU2686670C2 (ru) 2019-04-30

Family

ID=51982657

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015128496A RU2686670C2 (ru) 2013-10-04 2014-10-03 Лечение аллергического ринита с использованием комбинации мометазона и олопатадина

Country Status (12)

Country Link
US (1) US10646500B2 (enExample)
EP (2) EP2922553A1 (enExample)
JP (3) JP6419195B2 (enExample)
CN (2) CN105792828A (enExample)
HK (1) HK1215674A1 (enExample)
MX (2) MX2015009429A (enExample)
MY (1) MY176808A (enExample)
PH (1) PH12015502302A1 (enExample)
RU (1) RU2686670C2 (enExample)
UA (1) UA120587C2 (enExample)
WO (1) WO2015049665A1 (enExample)
ZA (1) ZA201504740B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
MX2015009429A (es) * 2013-10-04 2015-10-09 Glenmark Pharmaceuticals Ltd Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina.
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
AU2018260934B2 (en) * 2017-06-28 2023-10-19 Glenmark Specialty S.A. Dispensing device and pharmaceutical compositions for the treatment of rhinitis
BR112020016817A2 (pt) * 2018-02-23 2020-12-15 Glenmark Specialty S.A. Método para tratar sintomas associados à rinite alérgica, método para fornecer um início de ação mais rápido para alívio da rinite alérgica e método para tratar um sujeito humano pediátrico que sofre de rinite alérgica
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
AU7859800A (en) 1999-10-08 2001-04-23 Schering Corporation Topical nasal treatment
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
PL376970A1 (pl) * 2002-11-12 2006-01-23 Alcon, Inc. Zastosowanie środka przeciwalergicznego i steroidu do leczenia alergicznego nieżytu nosa
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
CA2586553C (en) 2004-11-24 2015-02-10 Alcon, Inc. Nasal sprayer containing a formulation with olopatadine
SI1919450T1 (sl) * 2005-09-01 2014-10-30 Meda Ab Liposomski sestavek, ki vsebuje antihistaminik in kortikosteroid, in njegova uporaba za izdelavo zdravila za zdravljenje rinitisa in sorodnih motenj
WO2007064912A2 (en) 2005-12-02 2007-06-07 Elan Pharma International Limited Mometasone compositions and methods of making and using the same
WO2007123193A1 (ja) 2006-04-21 2007-11-01 Toko Yakuhin Kogyo Kabushiki Kaisha スプレー用ゲルタイプ皮膚・粘膜付着型製剤およびそれを用いた投与システム
CN101795565A (zh) * 2007-06-28 2010-08-04 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
KR20110045004A (ko) * 2008-07-15 2011-05-03 쉐링 코포레이션 충혈제거제 및 코르티코스테로이드를 포함하는 비강내 조성물
WO2010025236A1 (en) 2008-08-27 2010-03-04 Alexander Goldin Composition and method for treating colds
CN102470099A (zh) 2009-07-17 2012-05-23 爱尔康研究有限公司 儿童用奥洛他定鼻腔喷雾方案
CN102078285A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有皮质激素和h1受体拮抗剂的鼻用原位凝胶
CN102078326A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有聚维酮碘与糠酸莫米松的局部使用组合物
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
EP2736491B1 (en) 2011-01-04 2017-04-05 Bausch & Lomb Incorporated Bepotastine compositions
BR112015009087A2 (pt) 2012-10-25 2017-11-14 Novozymes As método para lavagem de louça manual, e, composição detergente
KR20140081925A (ko) * 2012-12-12 2014-07-02 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제
PH12016500433B1 (en) 2013-09-13 2023-03-01 Glenmark Pharmaceuticals Ltd Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
MX2015009429A (es) * 2013-10-04 2015-10-09 Glenmark Pharmaceuticals Ltd Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina.

Also Published As

Publication number Publication date
RU2686670C2 (ru) 2019-04-30
EP4272839A2 (en) 2023-11-08
JP2018123157A (ja) 2018-08-09
US20150099725A1 (en) 2015-04-09
PH12015502302B1 (en) 2016-02-15
JP2020097624A (ja) 2020-06-25
WO2015049665A1 (en) 2015-04-09
EP4272839A3 (en) 2024-01-03
RU2015128496A (ru) 2017-11-13
PH12015502302A1 (en) 2016-02-15
RU2019104453A (ru) 2019-03-28
CN105792828A (zh) 2016-07-20
US10646500B2 (en) 2020-05-12
HK1215674A1 (zh) 2016-09-09
MX2020003035A (es) 2020-07-22
EP2922553A1 (en) 2015-09-30
JP2016531949A (ja) 2016-10-13
ZA201504740B (en) 2016-10-26
JP6419195B2 (ja) 2018-11-07
MY176808A (en) 2020-08-21
UA120587C2 (uk) 2020-01-10
MX2015009429A (es) 2015-10-09
CN112773808A (zh) 2021-05-11
JP6768733B2 (ja) 2020-10-14

Similar Documents

Publication Publication Date Title
AP2016009275A0 (enExample)
BR112016008927A2 (enExample)
BR112015007533A2 (enExample)
BR112014018502A2 (enExample)
BR112014019326A2 (enExample)
BR112014018480A2 (enExample)
BR112014018516A2 (enExample)
BR112014020341A2 (enExample)
BR112014017855A2 (enExample)
BR112014017765A2 (enExample)
BR112014021878A2 (enExample)
BR112014018468A2 (enExample)
BR112014019204A2 (enExample)
BR112014018207A2 (enExample)
BR112016011111A2 (enExample)
BR112015015948A2 (enExample)
BR112015029760A2 (enExample)
BR112015030603A2 (enExample)
BR112014018578A2 (enExample)
BR112014018483A2 (enExample)
BR112014017794A2 (enExample)
BR112016008778A2 (enExample)
BR112015015312A2 (enExample)
BR112014024039A2 (enExample)
BR112014018353A2 (enExample)